The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...

Three major drug middlemen needlessly marked up generic drugs for cancer, HIV, and multiple sclerosis to generate $7.3 ...

UnitedHealth reported fourth-quarter results on Thursday that reflected persistent challenges for the health insurance sector ...

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...

Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. charged significantly more than the national average ...

WASHINGTON >> The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain ...

The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...

Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...

(Bloomberg) -- Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc ... in “excess” revenue over six years, the Federal Trade Commission said in a report on the drug middlemen.

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.